Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis-Reference-Cited by-同舟云学术

Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis

Published:2024-09-10 Issue:9 Volume:2024 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ridley Ben¹,Minozzi Silvia²,Gonzalez-Lorenzo Marien³,Del Giovane Cinzia⁴⁵,Piggott Thomas⁶⁷,Filippini Graziella⁸,Peryer Guy⁹,Foschi Matteo¹⁰¹¹,Tramacere Irene¹²,Baldin Elisa¹,Nonino Francesco¹

Affiliation:

1. IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy

2. Department of Epidemiology; Lazio Regional Health Service; Rome Italy

3. Laboratorio di Metodologia delle revisioni sistematiche e produzione di Linee Guida; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Milan Italy

4. Institute of Primary Health Care (BIHAM); Bern Switzerland

5. Department of Medical and Surgical Sciences; University of Modena and Reggio Emilia; Modena Italy

6. Department of Health Research Methods, Evidence, and Impact; McMaster University; Hamilton, Ontario Canada

7. Department of Family Medicine; Queens University; Kingston, Ontario Canada

8. Scientific Director’s Office; Fondazione IRCCS, Istituto Neurologico Carlo Besta; Milan Italy

9. School of Health Sciences; University of East Anglia; Norwich UK

10. Department of Neuroscience, Multiple Sclerosis Center - Neurology Unit, S.Maria delle Croci Hospital; AUSL Romagna; Ravenna Italy

11. Department of Biotechnological and Applied Clinical Sciences; University of L'Aquila; L'Aquila Italy

12. Department of Research and Clinical Development, Scientific Directorate; Fondazione IRCCS Istituto Neurologico Carlo Besta; Milan Italy

Publisher

Wiley

Reference143 articles.

1. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis;Andersen;J Neurol Neurosurg Psychiatry,2004

2. A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO) https://clinicaltrials.gov/ct2/show/NCT02284568

3. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis;Giovannoni;Neurology,2020

4. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension;Kapoor;Lancet Neurol,2018

5. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis;Bornstein;Neurology,1991